Overview

Double-Blind, Randomized, Placebo-Controlled, Adaptive Design, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects

Status:
Recruiting
Trial end date:
2021-11-01
Target enrollment:
Participant gender:
Summary
The study is a double-blind, randomized, placebo-controlled, adaptive design, multi-center, Phase 3 study to evaluate the efficacy and safety of fostamatinib in COVID-19 subjects.
Phase:
Phase 3
Details
Lead Sponsor:
Rigel Pharmaceuticals